Intervention not reported
Ranibizumab · people with diabetic macular oedema
1 finding from 1 review
Intervention not reported
Ranibizumab deferred laser · people with diabetic macular oedema
1 finding from 1 review
Intervention not reported
Ranibizumab prompt laser · people with diabetic macular oedema
1 finding from 1 review
Intervention not reported
Laser · people with diabetic macular oedema
1 finding from 1 review
Intervention not reported
Faricimab (PTI) · people with diabetic macular oedema
1 finding from 1 review
Intervention not reported
Aflibercept · people with diabetic macular oedema
1 finding from 1 review
Intervention not reported
Brolucizumab · people with diabetic macular oedema
1 finding from 1 review
Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, 4 to 6 weeks · people with neovascular glaucoma
Anti‐VEGF may leads to higher proportion of participants with IOP ≤ 21 mmHg, with or without… compared with no anti‐VEGF (low certainty).
1 finding from 1 review
Mean IOP ( · people with neovascular glaucoma
It is very uncertain whether anti‐VEGF changes mean IOP, 4 to 6 weeks compared with no anti‐VEGF (very low certainty).
1 finding from 1 review
Visual acuity · people with neovascular glaucoma
It is very uncertain whether anti‐VEGF changes proportion of participants with improvement in visual acuity of 2… compared with no anti‐VEGF (very low certainty).
1 finding from 1 review
Proportion of participants with complete regression of new iris vessels, 4 to 6 weeks · people with neovascular glaucoma
Anti‐VEGF may leads to higher proportion of participants with complete regression of new iris… compared with no anti‐VEGF (low certainty).
1 finding from 1 review
Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events assessed in various ways, up to 24 months · people with neovascular glaucoma
1 finding from 1 review
no estimate extracted
6 participants
GRADE not reported
Intervention not reported
Mean BCVA (logMAR) · people with proliferative diabetic retinopathy undergoing vitrectomy
The intervention showed no clear difference in mean BCVA (logMAR) (low certainty).
1 finding from 1 review
Intervention not reported
Early POVCH Â · people with proliferative diabetic retinopathy undergoing vitrectomy
The intervention probably leads to lower early POVCH Â (moderate certainty).
1 finding from 1 review
Intervention not reported
Late POVCH Â · people with proliferative diabetic retinopathy undergoing vitrectomy
The intervention leads to lower late POVCH Â (high certainty).
1 finding from 1 review
Intervention not reported
Revision surgery for POVCH · people with proliferative diabetic retinopathy undergoing vitrectomy
The intervention showed no clear difference in revision surgery for POVCH (moderate certainty).
1 finding from 1 review
Intervention not reported
Revision surgery for recurrent traction and/or RRD · people with proliferative diabetic retinopathy undergoing vitrectomy
The intervention showed no clear difference in revision surgery for recurrent traction and/or RRD (low certainty).
1 finding from 1 review
Intervention not reported
Intraoperative retinal breaks · people with proliferative diabetic retinopathy undergoing vitrectomy
The intervention leads to lower intraoperative retinal breaks (high certainty).
1 finding from 1 review
Intervention not reported
Silicone oil use · people with proliferative diabetic retinopathy undergoing vitrectomy
It is very uncertain whether the intervention changes silicone oil use (very low certainty).
1 finding from 1 review